Rigel Pharmaceuticals (RIGL) Given Daily Coverage Optimism Rating of 0.24
Media headlines about Rigel Pharmaceuticals (NASDAQ:RIGL) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rigel Pharmaceuticals earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.4446742246508 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Rigel Pharmaceuticals, Fostamatinib Clinical Trials and Pipeline Review (finance.yahoo.com)
- Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares (finance.yahoo.com)
- Zacks Investment Research Upgrades Rigel Pharmaceuticals, Inc. (RIGL) to Hold (americanbankingnews.com)
- 13360398 shares of Rigel Pharmaceuticals, Inc. (RIGL) changed at hands actively on Oct 5, 2017 – Voice Of Analysts (analystsbuzz.com)
- Rigel Pharmaceuticals, Inc. (RIGL)- Safe Haven Performance Portfolio Stocks – NASDAQ Times (nasdaqtimes.com)
Rigel Pharmaceuticals (NASDAQ RIGL) traded down 2.04% during mid-day trading on Thursday, reaching $3.85. 826,194 shares of the company traded hands. The firm’s 50-day moving average is $2.73 and its 200 day moving average is $2.68. Rigel Pharmaceuticals has a 52-week low of $1.94 and a 52-week high of $4.07. The stock’s market capitalization is $478.91 million.
Rigel Pharmaceuticals (NASDAQ:RIGL) last released its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Rigel Pharmaceuticals had a negative return on equity of 105.86% and a negative net margin of 354.14%. During the same quarter last year, the company posted ($0.15) earnings per share. On average, equities research analysts expect that Rigel Pharmaceuticals will post ($0.60) earnings per share for the current year.
Several analysts have recently weighed in on RIGL shares. BMO Capital Markets restated an “outperform” rating and set a $5.00 price objective (up previously from $4.00) on shares of Rigel Pharmaceuticals in a research report on Monday, June 19th. ValuEngine downgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. BidaskClub downgraded shares of Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Zacks Investment Research downgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, Jefferies Group LLC restated a “buy” rating and set a $5.00 price objective on shares of Rigel Pharmaceuticals in a research report on Tuesday, September 5th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $6.75.
WARNING: “Rigel Pharmaceuticals (RIGL) Given Daily Coverage Optimism Rating of 0.24” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/rigel-pharmaceuticals-rigl-given-daily-coverage-optimism-rating-of-0-24/1626466.html.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.
Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.